Silo Pharma Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Eric Weisblum

Amministratore delegato

US$569.0k

Compenso totale

Percentuale dello stipendio del CEO	61.5%
Mandato del CEO	11.8yrs
Proprietà del CEO	4.1%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Silo Pharma spikes on pre-clinical data for Alzheimer's candidate

Oct 20

Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia

Oct 03

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Eric Weisblum rispetto agli utili di Silo Pharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$4m
Jun 30 2024	n/a	n/a	-US$3m
Mar 31 2024	n/a	n/a	-US$4m
Dec 31 2023	US$569k	US$350k	-US$4m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$4m
Dec 31 2022	US$332k	US$223k	-US$4m
Sep 30 2022	n/a	n/a	-US$3m
Jun 30 2022	n/a	n/a	US$4m
Mar 31 2022	n/a	n/a	US$4m
Dec 31 2021	US$345k	US$175k	US$3m
Sep 30 2021	n/a	n/a	US$3m
Jun 30 2021	n/a	n/a	-US$4m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$725k	US$115k	-US$3m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	n/a	n/a	-US$1m
Dec 31 2019	US$199k	US$91k	-US$1m
Sep 30 2019	n/a	n/a	-US$1m
Jun 30 2019	n/a	n/a	-US$1m
Mar 31 2019	n/a	n/a	-US$1m
Dec 31 2018	US$60k	n/a	-US$969k
Sep 30 2018	n/a	n/a	-US$290k
Jun 30 2018	n/a	n/a	-US$611k
Mar 31 2018	n/a	n/a	-US$371k
Dec 31 2017	US$60k	n/a	US$357k

Compensazione vs Mercato: La retribuzione totale di Eric ($USD 569.01K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 646.00K ).

Compensazione vs guadagni: La retribuzione di Eric è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Eric Weisblum (54 yo)

11.8yrs

Mandato

US$569,009

Compensazione

Mr. Eric Weisblum has been the Chief Executive Officer and Chairman of the Board of Silo Pharma, Inc. (formerly known as, Uppercut Brands Inc.) since November 27, 2015 and has been its President and Direct...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric Weisblum	Chairman	11.8yrs	US$569.01k	4.13% $ 161.5k
Charles Nemeroff	Member of Scientific Advisory Board	3.9yrs	Nessun dato	Nessun dato
Wayne Linsley	Independent Director	4.8yrs	US$45.00k	0% $ 0
Kevin Munoz	Independent Director	4.1yrs	US$25.00k	0% $ 0
Joshua Woolley	Member of Scientific Advisory Board	4yrs	Nessun dato	Nessun dato
Jeff Pavell	Independent Director	2.2yrs	US$25.00k	Nessun dato

4.0yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SILO sono considerati esperti (durata media dell'incarico 4 anni).

Silo Pharma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024

Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Silo Pharma, Inc. Announces Positive Results for Novel Spc-15 Treatment Targeting Stress-Related Disorders

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023)

Silo Pharma, Inc. Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024

Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.32 loss in 2Q 2023)

Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.100005 million.

Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.100005 million.

Silo Pharma, Inc. announced that it has received $2.077409 million in funding

New minor risk - Shareholder dilution

Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.000002 million.

Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.000002 million.

New major risk - Share price stability

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.29 loss in 1Q 2023)

Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment

Full year 2023 earnings: EPS misses analyst expectations

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

New minor risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations

Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA

Silo Pharma, Inc. Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.33 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.31 loss in 1Q 2022)

Silo Pharma, Inc. Announces Spc-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’S Disease

Full year 2022 earnings released: US$1.71 loss per share (vs US$1.45 profit in FY 2021)

Silo Pharma Announces Filing of Patent for Treatment of Alzheimer's

Silo Pharma, Inc. (NasdaqCM:SILO) announces an Equity Buyback for $1 million worth of its shares.

Silo Pharma, Inc. Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

Silo Pharma, Inc. Initiates Study of Novel Joint Homing Peptide in Human Tissue

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$3.28 profit in 3Q 2021)

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Silo Pharma, Inc. Announces Data Supporting Therapeutic Potential of SPC -14 for Alzheimer's Disease in Pre-Clinical Study

Silo Pharma spikes on pre-clinical data for Alzheimer's candidate

Investor sentiment improved over the past week

High number of new and inexperienced directors

Silo Pharma Initiates Toxicity Study of Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Silo Pharma, Inc. Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia

Silo Pharma, Inc. Announces Positive Results from its Topically Administered Formulation of Ketamine

Silo Pharma, Inc. Announces Positive Results in Subcutaneous Delivery of Its Novel Liposomes to Treat Arthritic Patients

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study

Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

Silo Pharma, Inc. Enters into Exclusive Option Agreement with the University of Maryland, Baltimore for Patented Homing Peptides Targeting Rheumatoid Arthritis

Silo Pharma, Inc. Enters into A Master License Agreement with the University of Maryland, Baltimore

Silo Pharma Inc. announced that it expects to receive $4.276 million in funding

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Silo Pharma Inc. Announces Licensing Agreement with Aikido Pharma Inc

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Silo Pharma, Inc. Appoints Charles B. Nemeroff to Scientific Advisory Board

Silo Pharma Inc. Appoints Peter Hendricks to its Scientific Advisory Board

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’S Disease

Silo Pharma, Inc. Names Joshua Woolley to Newly Formed Scientific Advisory Board

Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Matthew Johnson of John Hopkins University

Silo Pharma, Inc. Enters into Option Agreement with University of Maryland Baltimore for Central Nervous System-Homing Peptides

Silo Pharma, Inc. Appoints Kevin Muñoz to Board of Directors

Analisi delle retribuzioni degli amministratori delegati